Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK8 | P45983 | 10/20 | 0.62 |
| ▸ | MAPK9 | P45984 | 6/20 | 0.61 |
| ▸ | SYK | P43405 | 7/20 | 0.46 |
| ▸ | JAK2 | O60674 | 1/20 | 0.43 |
| ▸ | JAK1 | P23458 | 1/20 | 0.43 |
| ▸ | JAK3 | P52333 | 1/20 | 0.43 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
| ▸ | NNMT | P40261 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14657672 | 0.83 | MAPK8 (0.62) | MAPK8MAPK9SYKJAK2JAK1 | |
| SCHEMBL20920632 | 0.81 | SYK (0.44) | MAPK8MAPK9SYKNNMT | |
| SCHEMBL17088506 | 0.81 | MAPK8 (0.60) | MAPK8MAPK9SYKJAK2JAK1 | |
| SCHEMBL14657223 | 0.81 | MAPK8 (0.60) | MAPK8MAPK9SYKJAK2JAK1 | |
| SCHEMBL14657225 | 0.81 | MAPK8 (0.60) | MAPK8MAPK9SYKJAK2JAK1 | |
| SCHEMBL14667275 | 0.81 | MAPK8 (0.60) | MAPK8MAPK9SYKJAK2JAK1 | |
| SCHEMBL13734269 | 0.81 | MAPK8 (0.53) | MAPK8MAPK9SYKJAK2JAK1 | |
| SCHEMBL762022 | 0.80 | SYK (0.52) | MAPK8MAPK9SYKNNMT | |
| SCHEMBL13733963 | 0.79 | MAPK8 (0.51) | MAPK8MAPK9SYKJAK2JAK1 | |
| SCHEMBL20920664 | 0.78 | MAPK8 (0.57) | MAPK8MAPK9SYKJAK2JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10266500-B2 | Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2019-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10266500-B2 | Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith | MAP3K2, HDGF, MAP3K1 | MAPK8 45/4885MAPK9 87/4885SYK 2460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.